A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes Mellitus

NCT07313813 · Active, not recruiting

Last updated 2026-05-28

This study is testing how different fasting times and stopping a diabetes medication called dulaglutide affect stomach emptying in adults with type 2 diabetes after eating a solid meal.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) basic-science study

Participants 20 people Planned (estimated).

Who can join Ages 21–70 · all sexes

Timeline Started 2025-12 · est. completion 2026-08

Where 1 site · Singapore

What this study is testing ClinicalTrials.gov NCT07313813 ↗

Description as written by the study sponsor.

The purpose of this study is to evaluate how fasting and stopping the use of Dulaglutide (LY2189265) affect the amount of food and drink that stays in your stomach after a meal. Ultrasound devices will be used to check the stomach content after a test meal. The study can last approximately 28 weeks.

Treatments tested

Dulaglutide Drug

Administered SC

Main thing measured	Percentage of Fasting Participants with Lack of Gastric Content Retention Post-Solid Test Meal
Sponsor	Eli Lilly and Company
Conditions studied	Type 2 Diabetes Mellitus (T2DM)
GLP-1 drugs	dulaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07313813 ↗